Copyright
©2010 Baishideng.
World J Gastroenterol. May 28, 2010; 16(20): 2484-2495
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2484
Published online May 28, 2010. doi: 10.3748/wjg.v16.i20.2484
Case No. | Sex | Age (yr) | Type of disease | Anal lesion | Disease duration | Previous segmental resection | Initial onset or relapse | Hospitalization | |||||||
Fistula | Tag | On admission | Main medication | Duration of SVD (d) | On discharge | ||||||||||
CDAI | CRP (mg/dL) | CDAI | CRP (mg/dL) | Morphology | |||||||||||
1 | F | 52 | C | - | - | < 1 mo | - | I | 161 | 0.6 | Sulfasalazine | 58 | 25 | 0.9 | Active (CS) |
2 | M | 22 | C | + | + | 4 yr and 3 mo | + | R | 264 | 3.1 | Infliximab | 55 | 62 | 0 | NT |
3 | F | 21 | EC | + | - | 5 yr and 8 mo | - | R | 133 | 6.3 | Infliximab | 48 | 38 | 0 | NT |
4 | M | 22 | EC | + | - | 5 yr and 3 mo | - | R | 679 | 5.9 | Infliximab | 82 | 72 | 0.1 | Remission (CS) |
5 | M | 23 | EC | + | - | < 2 mo | - | I | 235 | 1.5 | Infliximab | 55 | 98 | 0.1 | Near remission (CS) |
6 | M | 28 | C | - | - | 2 mo | - | I | 88 | 2.5 | Infliximab | 68 | 59 | 0.5 | Near remission (CS) |
7 | F | 77 | C | - | - | 1 yr and 10 mo | - | R | 233 | 13.8 | Infliximab | 49 | 39 | 0 | Remission (CS and BE) |
8 | M | 30 | C | + | - | 6 mo | - | I | 281 | 4.6 | Infliximab | 50 | 39 | 0.1 | Remission (CS) |
9 | M | 55 | C | + | + | 8 mo | - | I | 172 | 1.0 | Infliximab | 46 | 67 | 0.5 | Remission (CS and BE) |
10 | M | 19 | EC | + | - | 4 mo | - | I | 147 | 0.8 | Infliximab | 43 | 40 | 0 | Remission (CS and BE) |
11 | F | 21 | EC | - | + | 3 mo | - | I | 335 | 6.0 | Infliximab | 49 | 47 | 0.3 | Improved still active (CS and BE) |
12 | F | 50 | E | - | - | 1 mo | - | I | 488 | 5.1 | Infliximab | 43 | 53 | 0 | Remission (CS) |
13 | M | 28 | C | - | - | 3 mo | - | I | 52 | 0.6 | Infliximab | 50 | 2 | 0 | Remission (CS) |
14 | M | 19 | EC | + | + | 2 yr and 1 mo | - | I | 193 | 0.8 | Infliximab | 43 | 35 | 0 | Near remission (CS and BE) |
15 | M | 29 | C | + | - | 1 yr and 4 mo | - | I | 126 | 0.2 | Infliximab | 43 | 8 | 0 | Improved still active (CS) |
16 | M | 30 | C | + | - | 1 yr and 1 mo | - | I | 211 | 11.8 | Infliximab | 47 | 28 | 0.8 | Near remission (CS and BE) |
17 | F | 21 | EC | - | + | 6 yr and 2 mo | - | R | 544 | 3.7 | Infliximab | 46 | 64 | 0.3 | Improved still active (BE) |
18 | F | 45 | EC | - | - | 13 yr | + | R, PO 21st d | 143 | 0.2 | Metronidazole | 19 | 105 | 0.1 | NT |
19 | M | 21 | EC | + | + | 2 yr | - | I, PO 13th d | 217 | 1.1 | Metronidazole | 18 | 166 | 0.1 | NT |
20 | M | 34 | EC | - | - | 17 yr | - | R, PO 12th d | 146 | 0 | Metronidazole | 24 | 108 | 0.1 | NT |
21 | M | 25 | C | - | + | 13 yr | - | R, PO 17th d | 372 | 7.1 | Metronidazole | 21 | 149 | 0 | NT |
22 | F | 23 | EC | - | - | 8 yr | - | R, PO 25th d | 151 | 8.0 | Metronidazole | 83 | 141 | 0.8 | NT |
- Citation: Chiba M, Abe T, Tsuda H, Sugawara T, Tsuda S, Tozawa H, Fujiwara K, Imai H. Lifestyle-related disease in Crohn’s disease: Relapse prevention by a semi-vegetarian diet. World J Gastroenterol 2010; 16(20): 2484-2495
- URL: https://www.wjgnet.com/1007-9327/full/v16/i20/2484.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i20.2484